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Abstract Tissue factor (TF)-positive microvesicles from various sources can promote cellular
proliferation or alternatively induce apoptosis, but the determining factors are
unknown. In this study the hypothesis that the ratio of fVIIa:TF within microvesicles
determines this outcome was examined. Microvesicles were isolated from HepG2,
BxPC-3, 786-O, MDA-MB-231, andMCF-7 cell lines andmicrovesicle-associated fVIIa and
TF antigen and activity levels were measured. Human coronary artery endothelial cells
(HCAECs) were incubated with these puriﬁed microvesicles, or with combinations of
fVIIa-recombinant TF, and cell proliferation/apoptosis was measured. Additionally, by
expressing mCherry-PAR2 on HCAEC surface, PAR2 activation was quantiﬁed. Finally,
the activation of PAR2 on HCAEC or the activities of TF and fVIIa in microvesicles were
blocked prior to addition of microvesicles to cells. The puriﬁed microvesicles exhibited
a range of fVIIa:TF ratios with HepG2 and 786-O cells having the highest (54:1) and
lowest (10:1) ratios, respectively. The reversal from proapoptotic to proliferative was
estimated to occur at a fVIIa:TF molar ratio of 15:1, but HCAEC could not be rescued at
higher TF concentrations. The puriﬁed microvesicles induced HCAEC proliferation or
apoptosis according to this ruling. Blocking PAR2 activation on HCAEC, or inhibiting
fVIIa or TF-procoagulant function on microvesicles prevented the inﬂuence on HCAEC.
Finally, incubation of HCAEC with recombinant TF resulted in increased surface
exposure of fVII. The induction of cell proliferation or apoptosis by TF-positive
microvesicles is dependent on the ratio of fVIIa:TF and involves the activation of
PAR2. At lower TF concentrations, fVIIa can counteract the proapoptotic stimulus and
induce proliferation.
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Introduction
Tissue factor (TF) initiates the coagulation mechanism
through the formation of a complex with factor VIIa (fVIIa)
which then activates factors X and IX.1,2 TF is expressed on
the surface of cells and may be released as cell-derived
microvesicles following cellular activation.3–9 TF is capable
of initiating cellular signals in cells expressing this protein,
and also on exposure of recipient cells to exogenous TF-
containing microvesicles. TF signaling can alter the cellular
gene expression proﬁle10,11 and has been demonstrated to
include fVIIa activity and protease-activated receptor-2
(PAR2) activation.12–18 Furthermore, interaction with β-
integrins has also been implicated in inducing cell prolifera-
tion.14,19–21 TF signaling is particularly associated with a
high proliferative capacity in cancer cells.22–24 However,
while the proliferative potential has been associated with
the interaction of TF with fVIIa, the data on the requirement
for proteolytic function of fVIIa are not consistent.12,13 We
previously showed that the exposure of cells to low levels of
recombinant TF alone promotes entry into the cell cycle.25
However, the exposure of cells to high levels of TF addition-
ally induces cell cycle arrest at the G1/S checkpoint and can
lead to cell apoptosis.25–27 In addition, monocyte-derived
microparticles can induce cellular apoptosis in endothelial
cells28 and eosinophils lacking fVII becomemore susceptible
to apoptosis.29 Therefore, the magnitude of exposure to TF
may itself determine the outcome in the recipient cells.
Furthermore, the formation of TF–fVIIa complex is capable
of triggering signals via PAR2 directly, or alternatively
through the activation of factor Xa (fXa) and formation of a
tertiary complex.30,31 The activation of PAR2 has also been
shown to be essential in the signaling processes that are
initiated from the exposure of cells to TF.32,33
It has been shown that as a consequence of inﬂamma-
tion, disease, or injury, large quantities of TF are released
within microvesicles.34–37 These microvesicles interact with
endothelial cells and have also been shown to be cleared by
endocytosis.38 While the inability of cells to satisfactorily
process TF is detrimental to endothelial cells,27 acute expo-
sure of cells to TF can also induce cellular apoptosis.25,26,28
Therefore, prolonged exposure of the endothelial layer to
TF-containing microvesicles may give rise to endothelial
dysfunction and denudation as seen in chronic dis-
eases.6,39,40 Understanding the criteria by which TF-con-
taining microvesicles function, and determining the
characteristics that confer the proliferative and proapopto-
tic properties to the microvesicles, may lead to a new
understanding of the relationship between various inﬂam-
matory diseases such as cancer and atherosclerosis with the
onset and progression of vascular disease. In this study, it
was hypothesized that the ratio of fVIIa:TF within cell-
derived microvesicles is a determinant of the outcome of
the exposure of endothelial cells to the microvesicles. Con-
sequently, the ability of the fVIIa–TF complex, and cell-
derived microvesicles containing a range of molar ratios of
fVIIa:TF, to promote endothelial cell proliferation or alter-
natively apoptosis was evaluated.
Material and Methods
Cell Culture
Five cell lineswere selected to include a range of TF expression
and not on the basis of tissue of origin. BxPC-3 pancreatic
cancerand786-Orenal carcinomacell lines (ATCC,Teddington,
UnitedKingdom)werecultured inRPMI-1640medium,MCF-7
breast cancer cell line and HepG2 hepatocellular carcinoma
cell lines (ATCC) were cultured in EMEM, and MDA-MB-231
(ATCC) breast cancer cell lines were cultured in DMEM. All
media were supplemented with 10% (v/v) heat-inactivated
fetal calf serum (FCS) to ensure the lack of any functional
enzymes. Human coronary artery endothelial cells (HCAECs),
devoid of endogenous TF, were cultured inMVmedia contain-
ing 5% (v/v) FCS and growth supplements (PromoCell, Heidel-
berg, Germany). In some experiments, the cells were adapted
to serum-free medium prior to use.
Preparation and Analysis of the TF-Containing
Microvesicles
Cell lines were propagated in 25 cm2 ﬂasks, washed with
phosphate-buffered saline (PBS) pH 7.4 and adapted to
respective serum-free medium, for 1 hour prior to collection
by ultracentrifugation according to described procedures for
preparation and conﬁrmation of the microvesicles.38,41 The
functional density of the released microvesicles was deter-
mined using the Zymuphen MP-assay kit (Hyphen BioMed/
Quadratech, Epsom, United Kingdom) using the standards
provided with the kit. The particle densities were also
veriﬁed and the size distribution of microvesicles was also
examined by nanoparticle tracking analysis using a Nano-
sight NTA 2.3 instrument.38,41
Qualitative Analysis of fVII/fVIIa and fX/fXa Antigens
in the Microvesicles by Western Blot
The presence of fX and fVII antigen was detected by western
blot analysis. The samples were separated by 12% (w/v)
sodium dodecyl sulfate polyacrylamide gel electrophoresis
(SDS-PAGE), transferred onto nitrocellulose membranes,
blocked with TBST (10 mM Tris-HCl pH 7.4, 150 mM NaCl,
0.05% Tween-20). The membranes were then probed with a
mouse monoclonal anti-fX antibody (156106), or a rabbit
polyclonal anti-fVII antibody (both from R&D Systems,
Abingdon, United Kingdom), both diluted 1:2000 (v/v) in
TBST. The membranes were developed with alkaline phos-
phatase-conjugated goat antimouse or goat antirabbit anti-
bodies (Santa Cruz, Heidelberg, Germany) respectively,
diluted 1:4000 (v/v) and bands were visualized using the
Western Blue stabilized alkaline phosphatase substrate (Pro-
mega, Southampton, United Kingdom).
Quantitative Determination of TF and fVIIa Antigen
Levels in the Microvesicles
The TF antigen associated with the microvesicles was mea-
suredusing theQuantikineTF-ELISAkit (R&DSystems)and the
factor VII/VIIa antigen levels were determined using the
Assaymax FVII-ELISA kit (Assaypro/Universal Biologicals Ltd.,
Cambridge, United Kingdom) according to themanufacturers’
TH Open Vol. 3 No. 2/2019
TF:fVIIa Ratio in MV Determines Influence on Cells Madkhali et al. e133
instructions. To determine the cell surface fVIIa antigen in
HCAEC without detachment, cells (2  104) were treated as
required and then ﬁxed using 4% (v/v) formaldehyde. The cells
were washed and one set was permeabilized while the other
set was kept intact. Total and surface expression of fVII were
measured in situ, by incubating all sampleswith a rabbit anti-
fVIIa polyclonal antibody (10 µg/mL). The samples were then
probedwithaHRP-conjugatedgoat antirabbit antibody (dilute
1:1000 v/v) and developed using the TMB One-solution HRP
substrate (Promega). The absorption values were measured at
450 nm from which the percentage ratio of surface:total fVII
was calculated. In some experiments, the cells were subjected
to repeated exposure to TF at 60 minute intervals and the cell
surface fVII antigenwasmeasured and calculated as a percen-
tage of the original cell-surface fVII.
Measurement of TF, fVIIa, and fXa Activity
Microvesicle TF-fVIIa activities were measured by modiﬁca-
tion of previously described procedures.42,43 To measure TF
activity, microvesicle samples were incubated with fVIIa (10
nM) in HEPES-buffered saline (HBS) pH 7.4, containing 1%
(w/v) bovine serum albumin (BSA) and 5 mMCaCl2, together
with fX (100 nM) and a fXa chromogenic substrate (0.2 mM;
Hyphen) diluted in the same buffer (200 µL). The samples
were incubated for 60 minutes to develop the color. Aliquots
(150 µl) were then transferred to a 96-well plate containing
2% (v/v) acetic acid (50 µL) and the absorptions measured
immediately at 410 nm. The amount of fXa generated was
determined using a standard curve prepared using fXa (0–
20 nM; Enzyme Research Labs). To detect microvesicle-asso-
ciated fVIIa activity, exogenous fVIIa was omitted from the
above, and replaced with recombinant TF (1 U/mL). The
absorption measurements were compared with a set of
controls prepared using a range of fVIIa (0–10 nM) which
were supplemented with recombinant TF (1 U/mL) and
analyzed for fXa-generation potential as above. To examine
the levels of fXa activity, the microvesicles were diluted in
the buffer as above and incubated with the fXa substrate
alone. The absorption measurements were compared with a
set of controls prepared using a range of fXa as above.
Treatment of HCAEC with fVII:TF and Microvesicles
HCAEC (2  104) were incubatedwithmicrovesicles prepared
from the conditioned serum-freemedia from the different cell
lines, at microvesicle densities stated in the Results section.
Other sets of cells were incubated with combinations of
recombinant human TF (Innovin thromboplastin reagent;
Dade Behring, Deerﬁeld, United States) at a range of 0 to 10
U/mL (1 U/mL ¼ 1.3 ng/mL), and/or puriﬁed fVIIa (Enzyme
Research Labs, Swansea, United Kingdom) at a range of 0 to 10
nM. Cell numbers were determined at 24 hour, by staining
with crystal violet aspreviously described and calculated from
a standard curve.38 As further conﬁrmation of entry into the
cell cycle, the expression of cyclin D1mRNAwasmeasured by
reverse transcription polymerase chain reaction (RT-PCR) as
previously described.25 Total RNA was extracted using the
Ribozol solution (VWR, Lutterworth, United Kingdom). The
expression of cyclin D1mRNAwasmeasured by GoTaq 1-Step
RT-qPCR System (Promega, Southampton, United Kingdom)
using QuantiTect primers for cyclin D1 and β-actin (Qiagene,
Manchester, United Kingdom) and relative amounts deter-
mined using as a reference. In addition, cellular apoptosis was
quantiﬁed using the TiterTACS Colorimetric Apoptosis Detec-
tion Kit (AMS Biotechnology, Abingdon, United Kingdom)
according to the manufacturer’s instructions.27 The data for
apoptosis were expressed as the change in absorption mea-
sured at 450 nm. Furthermore, the expression of bax mRNA
was quantiﬁed in the cell samples according to described
procedures and using the reagents above, to further conﬁrm
the induction of cell apoptosis.25,27 In some experiments, the
microvesicles were preincubated with an inhibitory mouse
antihuman TF antibody (HTF-1; 20 µg/mL; eBioscience/
Thermo Scientiﬁc, Warrington, United Kingdom), a signal-
blocking antihuman TF antibody (10H10; 20 µg/mL; BD
Bioscience,Wokingham, United Kingdom), an inhibitory poly-
clonal rabbit antihuman fVIIa antibody (10 µg/mL; Abcam,
Cambridge,UnitedKingdom), or respective control isotype IgG
antibodies (20 µg/mL; New England Biolabs, Hitchin, United
Kingdom). In other experiments, the activation of PAR2 on
HCAEC was blocked by preincubation of cells with an inhibi-
tory anti-PAR2 antibody (SAM11; Santa Cruz Biotechnology,
Heidelberg, Germany) which was used at 20 µg/mL. Addition-
ally, sets of HCAEC were supplemented with PAR2-activating
peptide (PAR2-AP; SLIGKV) at a ﬁnal concentration of 20 µM,
simultaneously with the addition of themicrovesicles (Severn
Biotech Ltd, Kidderminster, United Kingdom). Finally, in some
experiments the cells were preincubated with Rivaroxaban
(purecompoundsuppliedbyBayer, Leverkusen,Germany)and
usedat therapeuticconcentrations (0.6µg/mL),whichwasalso
optimized against fXa prior to this study.44
Preparation of mCherry-PAR2 Hybrid and
Measurement of PAR2 Activation
To measure the activation of PAR2, a hybrid tandem protein
was expressed to contain mCherry, followed by full-length
PAR2. The hybrid protein was therefore designed so that the
proteolytic activation of PAR2 released mCherry from the cell
surface, into themedium. The cDNA for PAR2was ampliﬁedby
PCR from the hPAR2 VersaClone cDNA plasmid (R&D Systems)
using the forward (5′-GCTCAAGCTTATCCAAGGAACCAATA-
GATCCTC) and reverse (5′-CGGTGGATCCTTAATAGGAGGTCT-
TAACAGTGG) primers and then digested with BamHI and
HindIII restriction enzymes (1 U/mL; New England Biolabs).
The insert was ligated using the Instant Sticky-end ligase
master mix (New England Biolabs), at a molar ratio of 3:1
into a mCherry2-C1 vector (Addgene) which was predigested
with the sametworestriction enzymes. 5α-CompetentEscher-
ichia coli bacteria were transformed with the plasmid DNA
construct and colonies were selected from LB-agar plates
containing carbenicillin (100 µg/mL). The cells were propa-
gated and the positive colonies containing the mCherry-PAR2
construct were selected and conﬁrmed by sequencing (Euro-
ﬁns MWG, Wolverhampton, United Kingdom). Plasmid DNA
was harvested from the bacteria bymidi-prep (Promega Corp,
Southampton, United Kingdom), using a procedure that elim-
inates any residual endotoxins. HCAECswere transfectedwith
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the mCherry-PAR2 constructs and surface expression was
conﬁrmed by ﬂuorescencemicroscopy and also by comparing
to cells labeled with FITC-conjugated anti-PAR2 antibody. The
analysis was performed using a Zeiss Axio Vert.A1 inverted
ﬂuorescencemicroscopewith a40magniﬁcation (Carl Zeiss
Ltd, Welwyn Garden City, United Kingdom). The activation of
PAR2 was monitored by measuring the release of mCherry
following the proteolytic digestion of PAR2. HCAECs expres-
sing the hybrid proteinwere washedwith PBS and adapted to
serum-freemedium.SincemCherry ismultiplydigestedby the
proteolytic action of fXa, the release of mCherry from the cell
surface was only examined by incubation of cells with combi-
nations of recombinant TF (0–4 U/mL) and puriﬁed fVIIa (0–4
nM) for up to 60 minutes. Finally, the ability of microvesicles
derived fromHepG2,BxPC-3,786-O,MDA-MB-231, andMCF-7
cell lines, to release mCherry, was examined.
Statistical Analysis
All data represent the calculated mean values from the
number of experiments stated in each ﬁgure legend  the
calculated standard error of the mean. Statistical analysis
was performed using the Statistical Package for the Social
Sciences (SPSS Inc. Chicago, United States). Signiﬁcance was
determined using one-way ANOVA (analysis of variance) and
Tukey’s honest signiﬁcance test or where appropriate, by
paired t-test.
Results
The Ratio of fVIIa to TF Varies in Microvesicles Derived
from Different Cell Lines
Throughout the study, microvesicles were puriﬁed from
resting HepG2, BxPC-3, 786-O, MDA-MB-231, and MCF-7
cell lines in accordance to the diverse expression of TF,
irrespective of tissue of origin. The microvesicles were
puriﬁed by ultracentrifugation from serum-free conditioned
media according to established procedures.41 Prior to exam-
ining the inﬂuence of microvesicles on endothelial cell
proliferation and apoptosis, the microvesicle density, TF
antigen, fVII/fVIIa antigen, and fXa-generation potential of
the microvesicles were analyzed. The particle densities were
veriﬁed and the size distribution of microvesicles was also
examined by NTA (►Supplementary Fig. S1). Comparison of
similar quantities of microvesicles from the cells lines indi-
cated that both BxPC-2 and MDA-MB-231 microvesicles
contained the highest amounts of TF (►Fig. 1A), which is
in agreement with our previous study.45 Examination of fXa-
generation in the presence of supplemented fVIIa mostly
reﬂected the measured TF antigen in the microvesicles
(►Fig. 1B). Examination of the fVIIa bywestern blot indicated
the presence of active fVIIa in HepG2, MDA-MB-231, and
MCF-7 cell lines, frequently exhibiting multiple bands
(►Fig. 1C) which have previously been attributed to the
presence of glycosylation variants.46,47 Moreover, 786-O
and BxPC-3 cells contained relatively lower levels of fVIIa
asmeasured bywestern blot (►Fig. 1D). The amounts of fVIIa
were also reﬂected in the relative levels of fVIIa mRNA
expression in four of the cell lines (►Supplementary
Fig. S2) but was four orders of magnitude higher in HepG2
cells (not shown). The amounts of microvesicle-associated
fVIIwere then quantiﬁed using a fVII-ELISA kit (►Fig. 1E) and
were largely in line with those detected by western blot. In
the absence of exogenous fVIIa, microvesicles from HepG2,
MDA-MB-231, and MCF-7 cells possessed higher fXa-gen-
eration capacity indicating high fVIIa activity (►Fig. 1F),
which largely agreed with the level of fVII antigen in these
microvesicles (►Fig. 1E). In contrast, lower fVIIa activities
were detectable in microvesicles from BxPC-3 and 786-O cell
lines (►Fig. 1F). Preincubation of all microvesicles with an
inhibitory polyclonal anti-fVII antibody abolished the inher-
ent fVIIa activity measured as above (not shown). The fVII
and TF antigen quantities were then used to determine the
ratio of fVIIa antigen toTF antigen andwere established to be
highest in HepG2 cells and lowest in 786-O cells (►Fig. 1G).
The presence of fVIIa on the surface of microvesicles requires
calcium ions. It has been shown that microvesicles can
contain a high concentration of calcium ions,48 which is
released during the formation of microvesicles by calcium-
sensitive enzymes including calpains and gelsolins, and
therefore permits the nonspeciﬁc binding of fVIIa to the
microvesicle surface. Moreover, the concentration of fVIIa is
only pathophysiologically relevant as fVIIa/TF complex and is
therefore dictated by the concentration of TF and not fVIIa.
However, none of the microvesicles examined contained fX/
fXa antigen when examined by western blot, or possessed
any detectable fXa activity following incubationwith an fXa-
speciﬁc chromogenic substrate (not shown).
Cell Derived Microvesicles Differentially Inﬂuence
Endothelial Cells
The microvesicles derived from the cell lines were incubated
with HCAEC and the inﬂuence on cell proliferation or apop-
tosis was measured. Examination of HCAEC cell numbers
indicated that the greatest increases in cell numbers on
incubation with microvesicles are derived from HepG2 and
MCF-7 cells (►Fig. 2A and 2B). In addition, marginal
increases were observed with microvesicles from MDA-
MB-231 cells, but not BxPC-3 cells. These increases in cell
numbers were also reﬂected in the expression of cyclin D1 as
a marker for cell-cycle entry (►Fig. 2C). In contrast, supple-
mentation of HCAEC with microvesicles derived from 786-O
resulted in reduction in cell numbers compared with the
untreated sample. The next sets of experiments examining
the induction of apoptosis only were then focused onto
microvesicles derived from 786-O cells. These were com-
pared with the outcome from microvesicles derived from
BxPC-3 cells which had little inﬂuence. HCAECs were incu-
bated with three microvesicle densities (25–130 nM) from
each cell line. The rate of HCAEC apoptosis was then mea-
sured using a chromogenic TUNEL assay. Incubation of
HCAEC with 50 nM of 786-O cell-derived microvesicles
resulted in maximal level of cell apoptosis (►Fig. 2D
and 2E) but was not signiﬁcant with BxPC-3-derived micro-
vesicles. To further conﬁrm the increases in cellular apopto-
sis, the expression of baxmRNAwasmeasured and shown to
agree with the data using the TUNEL assay (►Fig. 2F).
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Fig. 1 Analysis of the TF and fVIIa content of microvesicles. Five cell lines (HepG2, BxPC-3, 786-O, MDA-MB-231, and MCF-7) were propagated in 25 cm2
ﬂasks, washedwith phosphate-buffered saline (PBS) pH7.4 and adapted to respective serum-freemedium, for 1 hour.Microvesicleswere prepared from the
conditionedmedia by ultracentrifugation and the functional density determined using the ZymuphenMP-assay kit. (A) The TFantigen concentration of the
microvesicles was measured using the Quantikine TF-ELISA kit and (B) the associated TF activities were measured using the fXa-generation assay (n ¼ 5).
(C) Thepresenceof fVII/fVIIa antigen in thecellswasdetectedbywesternblot analysis. Thesampleswere separatedby12% (w/v) SDS-PAGE, transferredonto
nitrocellulosemembranes and then blocked with TBST (10 mMTris-HCl pH 7.4, 150 mMNaCl, 0.05% Tween-20). Themembranes were then probed with a
rabbit polyclonal anti-fVII antibody diluted 1:2000 (v/v) in TBST and developed with an alkaline phosphatase-conjugated goat antirabbit antibody, diluted
1:4000 (v/v). The bands were visualized using the Western Blue stabilized alkaline phosphatase-substrate and (D) quantiﬁed by ImageJ program. (The
micrographs are representative of three separate experiments). (E)Microvesicle-associated factorVII/VIIa antigen levelswerequantiﬁedusing theAssaymax
FVII-ELISAkit (n ¼ 5). (F)Microvesicle-associated fVIIaactivitywas alsomeasuredby fXa-generationassaybut in theabsenceofexogenous fVIIaandpresence
of TF (1 U/mL) (n ¼ 5). (G) Themolar ratio of fVIIa:TF inmicrovesicles derived from the cells lines was calculated using the data generated above. SDS-PAGE,
sodium dodecyl sulfate polyacrylamide gel electrophoresis; TF, tissue factor.
TH Open Vol. 3 No. 2/2019
TF:fVIIa Ratio in MV Determines Influence on Cells Madkhali et al.e136
The Ratio of fVIIa:TF within Microvesicles Determines
the Outcome on Endothelial Cells
To further examine the relevance of microvesicle-associated
fVIIa and TF, sets of HCAECs were incubated with combina-
tions of recombinant TF (0–10 U/mL; Innovin), in conjunc-
tion with three concentrations of fVIIa (0–10 nM). In the
absence of fVIIa, incubation of cells with recombinant TF
resulted in lowering of cell numbers (►Fig. 3A). Supplemen-
tationwith fVIIa (2 nM) partially prevented the decline in cell
numbers but became ineffective at TF concentrations higher
than 0.5 U/mL. Inclusion of 10 nM fVIIa restored the cell
numbers up to 2 U/mL of TF and was proliferative when
combined together with lower TF concentrations. It is also
noteworthy that in the absence of TF the addition of fVIIa had
no detectable effect. These data were also conﬁrmed by
titrating a range of concentrations of fVIIa, together with
three separate concentrations of TF. On supplementing the
cells with 0.5 U/mL of TF, increased HCAEC numbers were
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Fig. 2 Examination of the inﬂuence of cell line-derived microvesicles on HCAEC cell numbers. Microvesicles were prepared from cell lines
(HepG2, BxPC-3, 786-O, MDA-MB-231, and MCF-7), supplemented (50 nM) to HCAEC (2  104) and incubated in for up to 48 hours. (A) Cell
numbers were determined using the crystal violet staining assay and (B) the change in cell numbers was calculated as a percentage of the
untreated cells (n ¼ 5;  ¼ p < 0.05 vs. the respective untreated sample at each time point). (C) Total RNA was extracted from samples of the
treated HCAEC and the relative expression of cyclin D1 mRNA was analyzed by RT-PCR against β-actin as housekeeping (n ¼ 3;  ¼ p < 0.05 vs.
the untreated sample). Cellular apoptosis was also measured (as absorption at 450 nm) in sets of HCAEC using the TiterTACS chromogenic TUNEL
assay and (D) the change in level of apoptosis was calculated as a percentage of the untreated cells (n ¼ 5;  ¼ p < 0.05 vs. the untreated
sample). (E) Total RNAwas extracted from samples of the treated HCAEC and the relative expression of baxmRNAwas analyzed by RT-PCR against
β-actin as housekeeping (n ¼ 3;  ¼ p < 0.05 vs. the untreated sample). HCAEC, human coronary artery endothelial cell; RT-PCR, reverse
transcription polymerase chain reaction.
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Fig. 3 Examination of the effect of different ratios of fVIIa:TF on HCAEC cell numbers. (A) HCAECs (2  104) were incubated for 24 hours with a range of
recombinant humanTF (Innovin thromboplastin reagent) at a range of 0–10U/mL (1U/mL ¼ 1.3 ng/mL), in the presence or absence of puriﬁed fVIIa (0–10
nM).Cell numbersweredeterminedbycrystal violet stainingassay andpercentage change incell numbers calculated (n ¼ 5;  ¼ p < 0.05 vs. theuntreated
sample). (B) HCAECs (2  104)were also incubated for 24 hourswith a range of concentrations of puriﬁed fVIIa (0.1–10nM) in the presence of recombinant
humanTF (0–4U/mL).Cell numbersweredeterminedbycrystal violet stainingassayandpercentage change incell numbers calculated (n ¼ 5;  ¼ p < 0.05
vs. the untreated sample). Total RNAwas extracted fromsamples of the treatedHCAEC and the relative expressionof (C) cyclinD1mRNAand (D) baxmRNA
was analyzed by RT-PCR against β-actin as housekeeping (n ¼ 3;  ¼ p < 0.05 vs. the untreated sample). HCAEC, human coronary artery endothelial cells;
RT-PCR, reverse transcription polymerase chain reaction; TF, tissue factor.
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observed with all the concentrations of fVIIa tested
(►Fig. 3B). However, in the presence of 2 U/mL of TF, fVIIa
concentrations of 1 nM or higher were required to preserve
or increase the cell numbers. Furthermore, on addition of 4
U/mL of TF, only inclusion of 10 nM fVIIa was capable of
preventing the reduction in cell numbers. Analysis of cyclin
D1 and bax expression in HCAEC treated with recombinant
TF (2 U/mL) and puriﬁed fVIIa (0–10 nM) indicated entry into
the cell cycle regardless of fVIIa concentration, in agreement
with our previous ﬁndings,25 but was highest at 10 nM
(►Fig. 3C), while bax expression was only detectable at
lower fVIIa concentrations (►Fig. 3D).
Microvesicle-Induced Cell Proliferation and Apoptosis
is Mediated through PAR2
To explore the mechanisms involved in the induction of cell
proliferation and apoptosis by microvesicles, HCAECs were
preincubated with an antibody to prevent PAR2 activation
(SAM11; 20 µg/mL), prior to addition of microvesicles
derived from HepG2 or 786-O cell lines. Inhibition of PAR2
activation prevented the increase in HCAEC numbers in
response to microvesicles derived from HepG2 cell line, after
24 hours (►Fig. 4A). However, preventing the activation of
PAR2 using the antibody also suppressed the proapoptotic
inﬂuence of 786-O cell-derived microvesicles (►Fig. 4B).
Moreover, the analysis of cyclin D1 expression in HCAEC
stimulated with microvesicles derived from HepG2 cells
(►Fig. 4C) or bax mRNA in cells stimulated with microve-
sicles derived from 786-O cells (►Fig. 4D) conﬁrmed the
requirement for PAR2 activation in both the proliferative and
proapoptotic outcomes. Preincubation of 786-O microvesi-
cles, or alternatively theHCAECwith effective concentrations
of Rivaroxaban (0.6 µg/mL) to inhibit any present fXa, did not
prevent endothelial apoptosis (not shown). Moreover, simul-
taneous activation of PAR2 using the activating peptide
(SLIGKV; 20 µM) in conjunction with 786-O cell-derived
microvesicles (50 nM)was capable of rendering thesemicro-
vesicles ineffective (►Fig. 4E). To decipher these observa-
tions, the presence of PAR2 antigen on the surface of cell
surface, following the addition of PAR2-AP or a range of
concentrations of microvesicles from 786-O cells, was exam-
ined. The HCAECs were probed with a PAR2 antibody in situ,
to avoid nonspeciﬁc activation of PAR2 by trypsinization.
HCAECs were incubated with microvesicles from 786-O cells
at the optimal (50 nM) and hyper-optimal (130 nM) densities
to induce apoptosis (►Fig. 2E). Incubation of HCAEC with
PAR2-AP (20 µM) or with 130 nM of 786-O cell-derived
microvesicles resulted in signiﬁcant reductions in cell sur-
face PAR2 within 30 minutes (►Fig. 4F). In contrast, cell-
surface PAR2 levels remained unaltered by the addition of
50 nM of these microvesicles.
Microvesicles Differentially Activate PAR2 on the
Surface of Endothelial Cells
To examine the level of PAR2 activation in response to various
microvesicles, a hybrid construct was prepared containing
the cDNA for mCherry-PAR2 and was expressed in HCAEC.
The expression of the mCherry-PAR2 in HCAEC was con-
ﬁrmed by ﬂuorescencemicroscopy (►Fig. 5A). This was then
compared with the pattern of native PAR2 expression,
probed using Alexa Fluor488-conjugated anti-PAR2
(SAM11) antibody (►Fig. 5B). To determine the effectiveness
of the TF–fVIIa complex in activating PAR2, the transfected
cells were incubated with combinations of TF (0–4 U/mL)
together with fVIIa (0–10 nM) and the release of mCherry in
themediawasmeasured at Em. 630 nm (Ext. 580 nm). In the
absence of TF, the addition of fVIIa (0–10 nM) did not result in
the release of ﬂuorescence into the media (►Fig. 5C). More-
over, addition of TF alone, or together with low level of fVIIa
(0.5 nM), was not sufﬁcient to induce PAR2 activation.
Incubation of cells with TF together with fVIIa (2 nM)
resulted in marginal increases in ﬂuorescence, which was
signiﬁcant at higher TF concentrations. In contrast, inclusion
of fVIIa (10 nM) resulted in a TF concentration-dependent
activation of PAR2 from the transfected HCAEC. Examination
of the effectiveness of the microvesicles puriﬁed from the
ﬁve cell lines in activating mCherry-PAR2 expressed on the
surface endothelial cell conﬁrmed a high activity associated
with HepG2 and MCF-7-derived microvesicles, with lower
levels with MDA-MB-231 microvesicles but no signiﬁcant
PAR2 activation with microvesicles from BxPC-3 or 786-O
cells (►Fig. 5D).
Exogenous fVIIa Prevents TF-Microvesicle-Induced
Apoptosis
To test thehypothesis that increased levels of fVIIa can rescue
the cells from microvesicle-induced apoptosis, and may
induce proliferation, HCAECs were incubated with 786-O
cell-derived microvesicles in the presence or absence of
exogenous fVIIa (2 nM). Inclusion of additional fVIIa abol-
ished the proapoptotic inﬂuence of 786-O cell-derived
microvesicles (►Fig. 6A). However, as shown before
(►Fig. 3A), the supplementation with fVIIa in the absence
of any TF did not inﬂuence the HCAEC numbers which are
otherwise devoid of endogenous TF expression. Preincuba-
tion of 786-O microvesicles with an inhibitory anti-TF anti-
body (HTF-1; 20 µg/mL), which blocks the procoagulant
activity of TF, prevented cellular apoptosis (►Fig. 6B). How-
ever, preincubation of these microvesicles with the 10H10
anti-TF antibody, which inhibits TF signaling, or the isotype
control antibody did not interfere with the promotion of
apoptosis in HCAEC. In addition, neutralization of fVIIa in
microvesicles derived from 786-O and HepG2 cells, using an
inhibitory anti-fVIIa antibody, prevented the promotion of
cell apoptosis in response to 786-O-derived microvesicles
(►Fig. 6C) and also the increased cell numbers by HepG2-
derived microvesicles (►Fig. 6D), respectively. 10H10 anti-
body blocks TF signaling by blocking TF interaction with
integrins49,50 and the secondary/exosite PAR2-binding site
within TF.51 However, unlike HTF1, it does not prevent the
interaction with fVIIa,51 nor does it affect the proteolytic
activity of the TF/fVIIa complex.52 Therefore, in agreement
with the data using the inhibitory anti-fVIIa antibody
(►Fig. 6C), the initiation of the described mechanism is
dependent on the proteolytic activity of fVIIa as well as
requires TF.
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Endothelial Cells Release fVII in Response to TF
Examination of HCAEC by RT-PCR indicated the presence of
detectable amounts fVII mRNA in HCAEC (not shown).
Measurement of the fVII protein lying intact and lysed
HCAEC indicated that approximately 20% of the fVII was
exposed at the surface of the resting cells (►Fig. 7A). The
presence of fVII associated with caveolae andWeibel–Palade
bodies in differentiating endothelial cells has been demon-
strated53 and our unpublished data have shown some asso-
ciation of fVII with caveolae in resting endothelial cells
(Madkhali et al, unpublished data). However, stimulation
of HCAEC with recombinant TF (2 U/mL) resulted in a
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Fig. 4 Examination of the involvement of PAR2 in microvesicle-induced HCAEC apoptosis. Sets of HCAEC (2  104) were preincubated with a
blocking anti-PAR2 antibody (SAM11; 20 µ/mL) or a control isotype. Sets of cells were then incubated with microvesicles derived from (A) HepG2
cell line (50 nM) for 24 hours and cell numbers were determined by crystal violet staining assay (n ¼ 5;  ¼ p < 0.05 vs. the untreated sample,
# ¼ p < 0.05 vs. the sample devoid of antibody). (B) A similar set of cells was incubated for 24 hours with microvesicles derived from 786-O cell
line (50 nM) and the rate of apoptosis determined using the TiterTACS chromogenic TUNEL assay (n ¼ 5;  ¼ p < 0.05 vs. the untreated sample,
# ¼ p < 0.05 vs. the sample devoid of antibody). Total RNA was extracted from samples of the treated HCAEC and (C) the relative expression of
cyclin D1 mRNA, and (D) bax mRNA was analyzed by RT-PCR against β-actin as housekeeping (n ¼ 3;  ¼ p < 0.05 vs. the untreated sample,
# ¼ p < 0.05 vs. the sample devoid of antibody). (E) HCAECs (2  104) were incubated for 24 hours with microvesicles derived from 786-O cell
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signiﬁcant increase in cell surface fVII antigen (48% of the
cellular fVII), as measured by the in situ labeling. Further-
more, activation of HCAEC with PAR2-AP (20 µM) resulted in
a comparable but longer-term increase (33% of the cellular
fVII at 30 minutes) in the concentration of cell-surface fVII
(►Fig. 7B). In some experiments, HCAECs were subjected to
repeated treatment of cellswith recombinant TFat 60minute
intervals. In these experiments, both the remaining cell-
surface fVII and the microvesicle-associated fVII antigens
weremeasured as a percentage of that present on the surface
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of the resting cells. Treatment of HCAECwith recombinant TF
progressively decreased the amount of fVII present on the
cell surface (►Fig. 7C). Furthermore, themagnitudes of these
reductionswere accounted for by the amount of fVII that was
associated with the released microvesicles (►Fig. 7D).
Discussion
The exposure of TF at the site of injury acts to initiate the
coagulationmechanismand contains bleeding. However, as a
factor which appears early at the sight of injury, TF is ideally
placed to have a dual function in instructing the cells to
divide or become apoptotic. The distinction between the
severely injured cells and those which may be revived is
imperative in the precise vascular homeostasis. These func-
tional properties of TF also appear to be replicated in the
microvesicle-associated TFs that are released into the blood-
stream from various sources. In addition to TF, these micro-
vesicles may also contain a complement of negatively
charged phospholipids3–8 and functional fVIIa (►Fig. 1). It
is known that microvesicles from different sources exert
dissimilar inﬂuence on endothelial cells, which provides
crucial clues for the understanding of the destructive inﬂu-
ence of microvesicles in diseases.33–36 Therefore in this
study, by measuring the ratios of fVII/fVIIa and TF, we
examined a possible mechanism by which TF-containing
microvesicles may confer different outcomes in cultured
primary endothelial cells. In agreement with this hypothesis,
incubation of HCAECwith combinations of puriﬁed fVIIa and
recombinant TF resulted in different cellular outcomes
depending on the fVIIa:TF ratio. The transition from the
proapoptotic to proliferative property appears to occur at
an estimated fVIIa:TF molar ratio of 15:1. This was also in
agreement with the ratios observed in the microvesicles
puriﬁed from the cell lines. Particularly, the fVIIa:TF ratio
in the 786-O renal carcinoma cell line was 10:1 and these
microvesicles induced cellular apoptosis in HCAEC
(►Fig. 1G). Higher molar ratios of 54:1and 38:1 observed
in the HepG2 hepatocellular line and MCF-7 breast cancer
line (►Fig. 1) were concurrent with increased HCAEC pro-
liferation. Interestingly, the change in cell numbers was
signiﬁcantly proportional to the observed fVIIa:TF ratio
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(Pearson correlation ¼ 0.956; p ¼ 0.011). However, it also
appears that aswell as the fVIIa:TF ratio, the concentration of
TF with which the cell comes into contact with is an addi-
tional critical factor in determining the outcome. Therefore,
despite the similar fVIIa:TF molar ratios, microvesicles
derived from MDA-MB-231 (34:1) were signiﬁcantly less
proliferative than those derived fromMCF-7 cell lines (38:1).
This may therefore be explained by the much higher TF
content of microvesicles from MDA-MB-231 cells.
Although HCAEC lacked any detectable cell-surface TF, a
signiﬁcant proportion of cellular fVII was detected on the
surface of these endothelial cells (►Fig. 7). Furthermore,
activation of HCAEC with recombinant TF or PAR2-AP
resulted in the exposure of a higher proportion of the cellular
fVII. Therefore, it is possible that endothelial cells respond to
the stimulatory signals arising from injury/trauma by alter-
ing the fVIIa:TF ratio, to counter the proapoptotic inﬂuence
that arises from the presence of excessive levels of TF.
However, because in our studies only the amounts of exo-
genous fVIIa and TF were used in calculating the fVIIa:TF
molar ratios, the real ratios for the transition from the
proapoptotic to proliferative form are likely to be higher
than those reported here (15:1). In addition, repeated expo-
sure of HCAEC resulted in the depletion of cellular fVII
reserves (►Figs. 7C and 7D). Such a compromise in endothe-
lial cell function implies that the response by these cells may
become insufﬁcient in ensuring the survival of the cell.
Therefore, we hypothesize that repeated exposure to TF-
positive microvesicles, for example during chronic disease,
exhausts the ability of endothelial cells to counter the
proapoptotic property of TF.
To further elucidate the underlying proliferative mechan-
isms, PAR2, TF, and fVIIa were in turn inhibited using anti-
bodies. Inhibition of PAR2 prevented the proapoptotic
function of these microvesicles, indicating the requirement
for PAR2 activation. Moreover, overstimulation of the cells
with high concentrations of microvesicles or the addition of
PAR2-AP was less effective due to the endocytosis of PAR2
and desensitization of HCAEC. Both the proliferative and
proapoptotic inﬂuences of microvesicles were attributed to
the proteolytic activity of the fVIIa-TF complex and were
blocked by respective inhibitory antibodies. Finally, prein-
cubation of microvesicles or HCAEC with Rivaroxaban to
inhibit fXa did not prevent apoptosis inHCAEC.Microvesicles
derived from different cell lines may contain pro- and anti-
apoptotic/proliferative material which can then contribute
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Fig. 7 HCAECs express fVIIa on the cell surface in response toTF and PAR2 activation. Two separate sets of HCAEC (2  104) were incubated with
(A) TF (2 U/mL) or (B) PAR2-activating peptide (20 µM) for the durations shown and the cells were then ﬁxed using 4% (v/v) formaldehyde. The
cells were washed and one set was permeabilized while the other kept intact. Total and surface expression of fVII were measured in situ, by
incubating all samples with a mouse anti-fVIIa antibody (20 µg/mL). The samples were then probed with a HRP-conjugated goat antimouse
antibody (dilute 1:1000 v/v) and developed using the TMB substrate. The percentage ratio of surface:total fVII was then calculated (n ¼ 5;
 ¼ p < 0.05 vs. the observed ratio at time zero). HCAECs (2  104) were also subjected to repeated treatment with recombinant TF (2 U/mL) at
60 minute intervals. After each treatment, the relative amount of (C) cell-surface fVII antigen and (D) the released microvesicle-associated fVII
antigen were measured and the percentages were calculated against the amount of cell-surface fVII in the untreated cells. HCAEC, human
coronary artery endothelial cells; PAR2, protease-activated receptor-2; TF, tissue factor.
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to endothelial cell proliferation or apoptosis. However, by
selectively inhibiting TF or fVIIa (►Fig. 6), or alternatively
blocking PAR2 (►Fig. 4), using speciﬁc antibodies we have
demonstrated that these outcomes were initiated from the
fVIIa/TF complex. In addition, the use of recombinant TF and
puriﬁed fVIIa further conﬁrmed the role of TF and fVIIa
observed with cell-derived microvesicles (►Fig. 3). In con-
trast, activation of PAR2 in the absence of TF has been shown
not to induce a similar complement of the signaling pathway
and does not lead to apoptosis.27
This studyhas for theﬁrst timeshownthat the ratioof fVIIa:
TF determines the outcome in endothelial cells resulting in
either proliferationor apoptosis. This isparticularly relevant in
the case of TF-containing microvesicles which are released
during inﬂammatory conditions. The induction of cell prolif-
eration and apoptosis bymicrovesicles appears tobemediated
through the activation of PAR2, but the cellular outcome is
entirely dependent on the amount of TF protein and themolar
ratio of fVIIa-TF protease activity. However, the downstream
events are only partially elucidated. In conclusion, a novel
measurable parameterwithinprocoagulantmicrovesicles that
can determine the function ofmicrovesicles during the activa-
tion of the vasculature has been identiﬁed.
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